OWCP (OWC Pharmaceutical Research) Pretax Margin %: % (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OWC Pharmaceutical Research Pretax Margin %?

OWC Pharmaceutical Research OWCP Pretax Margin % is % as of Sep. 2019.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. OWC Pharmaceutical Research's Pre-Tax Income for the three months ended in Sep. 2019 was $-0.29 Mil. OWC Pharmaceutical Research's Revenue for the three months ended in Sep. 2019 was $0.00 Mil. Therefore, OWC Pharmaceutical Research's pretax margin for the quarter that ended in Sep. 2019 was %.

The historical rank and industry rank for OWC Pharmaceutical Research's Pretax Margin % or its related term are showing as below:


OWCP's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.285
* Ranked among companies with meaningful Pretax Margin % only.

OWC Pharmaceutical Research  (OTCPK:OWCP) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

OWC Pharmaceutical Research Pretax Margin % Related Terms

OWC Pharmaceutical Research Pretax Margin % Historical Data

* Premium members only.

The historical data trend for OWC Pharmaceutical Research's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OWC Pharmaceutical Research Pretax Margin % Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 -4,574.00 0.00 0.00

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OWCP vs PARNF, CANB, CXUS: Pretax Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, OWC Pharmaceutical Research's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OWC Pharmaceutical Research Pretax Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OWC Pharmaceutical Research's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where OWC Pharmaceutical Research's Pretax Margin % falls into.


OWC Pharmaceutical Research Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

OWC Pharmaceutical Research's Pretax Margin for the fiscal year that ended in Dec. 2018 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2018 )/Revenue (A: Dec. 2018 )
=-10.258/0
= %

OWC Pharmaceutical Research's Pretax Margin for the quarter that ended in Sep. 2019 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2019 )/Revenue (Q: Sep. 2019 )
=-0.287/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
OWC Pharmaceutical Research (OWCP) has a Pretax Margin % of % as of Sep. 2019. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on OWC Pharmaceutical Research and its competitors.
Is OWC Pharmaceutical Research's Pretax Margin % too high?
OWC Pharmaceutical Research's current Pretax Margin % is %.
How does OWC Pharmaceutical Research's Pretax Margin % compare to PARNF and CANB?
OWC Pharmaceutical Research's Pretax Margin % of % can be compared against companies in the Drug Manufacturers industry. The industry median Pretax Margin % is 7.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on OWC Pharmaceutical Research and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OWC Pharmaceutical Research's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OWC Pharmaceutical Research stock overvalued right now?
OWC Pharmaceutical Research (OWCP) has a current Pretax Margin % of %. The current Pretax Margin % is %. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For OWC Pharmaceutical Research (OWCP), the current Pretax Margin % is % as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OWC Pharmaceutical Research Business Description

Address 2 Ben Gurion Street, Ramat Gan, ISR, 4514760
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.